Below is a list of panelists and the times of their panels
Al Altomari, a 2020 PharmaVOICE Red Jacket, serves as Chairman and CEO of Agile Therapeutics, a forward-thinking women’s healthcare company dedicated to fulfilling the unmet health needs of today's women. He also serves on the company’s Board of Directors. Al helped revitalize the company to become a leader in women’s health. Previously, he was CEO and Chief Operating Officer at Barrier Therapeutics. He has held numerous executive roles in general management, commercial operations, business development, product launch preparation, and finance with Johnson & Johnson. Al also serves on the board of directors of Insmed and Baudax Bio and on the LeBow College of Business Advisory Board and the Board of the Charles D. Close School of Entrepreneurship at Drexel University. He also serves as Chairman of the TASK Trenton Area Soup Kitchen.
Follow on Twitter: @AlAltomari
Peter Anastasiou, a 2020 PharmaVOICE 100, serves as Executive VP and Head of North America for Lundbeck as well as a member of the company’s executive management team. Since joining Lundbeck, a global pharmaceutical company committed to improving the quality of life of people living with brain diseases, in 2009, he has held a variety of leadership positions and played a pivotal role in growing the business. Before joining Lundbeck, Peter held a series of leadership roles within neuroscience-focused pharmaceutical organizations, including Neuronetics and Bristol Meyers Squibb. He serves on the Board of Directors of Bear Necessities Pediatric Cancer Foundation and sits on the President’s Council of ChildServ. He is also on the Global Advisory Board for the Healthcare Businesswomen’s Association.
Follow on Twitter: @LundbeckUS
Sagar Anisingaraju, a 2020 PharmaVOICE 100, is Chief Strategy Officer at Saama Technologies, where he is driving the concepts, business models, and development of the company’s innovative analytics solutions. Sagar came to Saama, which harnesses and applies the power of artificial intelligence and deep learning to its proprietary analytics platform, through the 2010 acquisition of InfoSTEP, the analytics company he founded to help manage IT business value and business risk. His passion is to help pharma companies operationalize clinical data and accelerate drug development. In 2018, Sagar was awarded a patent for his work using Natural Language Understanding (NLU) for risk and compliance programs. He is the author of Kuchela.AI.
Elliot Barnathan, M.D., a 2020 PharmaVOICE 100, is Senior Director, Cardiovascular Clinical Development, at Janssen Research & Development, which discovers and develops innovative medicines and solutions that transform individuals’ lives and solves the most important unmet medical needs. Dr. Barnathan has been working with regulators, public health organizations, and specialty societies to ensure the best care for patients affected by the coronavirus. His pharmaceutical research career has spanned a range of diseases in cardiology, immunology, and pulmonology. He previously spent 10 years on the faculty at the University of Pennsylvania School of Medicine, where he received his M.D.
Follow on Twitter: @barnathanes
Senior Director, Cardiovascular Clinical Development, Janssen Research & Development
Jack Barrette, a 2019, 2006, and 2005 PharmaVOICE 100, is the Founder and CEO of WEGO Health, an online home for consumer health activists. He believes that the most lasting changes to people's health will be driven by their own empowerment — and viable, exciting business models that make it all possible for the long term. He is a life-long health marketer, serial entrepreneur, and Internet pioneer, having founded Mt. Vernon Partners, a consultancy focused on digital technologies, and ECHO Strategies Group, a health-focused agency. He has led the industry in building condition-specific patient communities, helping patients benefit from those communities, and bridging the gap between patients and pharma companies. Jack is also a former executive at Yahoo!, where he focused on lifestyles, health, and medicine.
Jeff Berkowitz, a PharmaVOICE Red Jacket is CEO and Director of Real Endpoints, which harnesses innovative tools to create high-value strategies for biopharmaceutical companies and payers. Jeff is one of the rare top executives whose career has spanned most key verticals in global healthcare — with executive committee and other senior roles at United Health Group, Walgreens Boots Alliance (formerly Walgreens), Merck and Schering-Plough. He joined Real Endpoints in 2018 as CEO from UnitedHealth Group/Optum where he led Optum’s International division as CEO while also driving key strategic initiatives within Optum’s pharmacy benefits management division. Prior to joining United, Jeff served as President of Pharma and Global Market Access at the Walgreens Boots Alliance, responsible for generic and branded procurement, inventory management, relationships with pharmaceutical companies as well as the companies pricing and reimbursement strategies with all payers and payer segments.
Ryan Billings, a 2020 PharmaVOICE 100, is Senior Director, Oncology Digital Marketing and Customer Experience, at GSK, which researches, develops, and manufactures innovative pharmaceutical medicines, vaccines, and consumer healthcare products. He is a leader in the healthcare space with deep expertise in enterprise digital transformation & strategy, innovation solution development and scale, digital health, social strategy, content marketing, brand communications, analytics, and mobile solutions. Before joining GSK, he was Executive Director, Digital Engagement, at AMAG Pharmaceuticals, where he rolled out a telemedicine capability for the women’s health franchise. He helped to launch the first branded Facebook community with open comments for a brand while at AstraZeneca.
Follow on Twitter: @ryandaniel @GSK
Head, US Oncology Digital Marketing & Customer Experience, GSK
Bill Byrom, Ph.D., a 2017 and 2008 PharmaVOICE 100, serves as VP, Product Strategy and Innovation for Signant Health, whose goal is to improve the lives of patients, sites, and study teams worldwide by providing simple, intuitive technology that simplifies clinical trials for everyone. Bill has worked in the pharmaceutical industry for 28 years. Combining practical experience of roles within clinical development with a keen interest in leveraging technology, Bill is a key strategic thinker helping to shape the direction and application of eClinical solutions. Bill is a thought leader in patient-facing technologies, including electronic patient-reported outcome solutions, the use of wearables and connected devices, and new novel technology-derived endpoints, helping to shape the application of eClinical solutions.
Follow on Twitter: @billbyrom @SignantHealth
VP, Product Strategy and Innovation, Signant Health
Sharon Callahan, a 2020 Red Jacket, was named CEO of CDM, a healthcare advertising agency based in the power of community, the power of diverse people and diverse thinking, and the beauty of collaboration, in March 2020, after leading TBWA\WorldHealth as CEO for four years. She also serves as Chief Client Officer of Omnicom Health Group. Sharon is an accomplished senior healthcare communications executive with proven general management experience in both public and private companies. With a consistent track record of building and growing businesses, she uses her sharp leadership and team-building skills to help clients leverage the value of their messages through the seamless integration of multiple communication channels, making sure that every message is on point at every contact point.
Follow on Twitter: @SharonFCallahan @CDMNY @OmnicomHealth
Laurie Cooke, a 2017 and 2009 PharmaVOICE 100, is the CEO and President of the Healthcare Businesswomen's Association (HBA), which is dedicated to furthering the advancement and impact of women in the business of healthcare. A dedicated advocate for gender parity, speaker, and thought leader, she is well-versed in commercializing insights across the career continuum and drug development from pre-clinical to post approval. She is an innovative problem solver, change agent, and proven leader who identifies and inspires talent to succeed, which led to her being named ASAE Mentor of the Year. Laurie previously served on PMI’s executive management team and before her nonprofit management career, she served in various roles with Hoechst, Hoechst Roussel, Hoechst Marion Roussel, and Aventis. Laurie began her career as a head hospital pharmacist in Washington State.
Follow on Twitter: @lcooke9 #HBAimpact
President and CEO, Healthcare Businesswomen's Association
Dr. Shannon Dahl, a 2018 PharmaVOICE 100, serves as Chief Scientific Officer of Cell Care Therapeutics, which is developing novel therapies derived from the secretions of adult stem cells to treat severe inflammatory and degenerative retinal diseases in patients who suffer from vision loss. She previously co-founded Humacyte, a pioneering regenerative medicine company, where she held leadership roles in technology, product translation, pipeline, corporate, and commercial development. Humacyte was named a "CNBC Disruptor 50" company. She holds more than 35 issued patents, authored more than 21 publications, and co-authored the first ever Regenerative Medicine Advanced Therapy designation granted by FDA. She serves on scientific and strategic advisory boards for cell and gene therapy companies.
Donald Deieso, Ph.D., a 2020 Red Jacket honoree, is Executive Chairman & CEO at WCG, whose goal is to measurably improve the quality and efficiency of clinical trials, helping biopharmaceutical companies, CROs, and institutions facilitate the development of new treatments and therapies for patients. He has devoted his life to public health and being a champion for patients of all backgrounds, all over the world. Particularly, his work has centered on improving the clinical trial experience for patients and their caregivers, spearheading numerous initiatives to transform research processes and accelerate their adoption across the life sciences industry. Dr. Deieso founded WIRB-Copernicus Group (WCG) in 2012 and has led its growth to an organization that now encompasses five operating divisions, 2,500 global employees, and over 25 office locations worldwide. Prior to WCG, Dr. Deieso was CEO of a number of publicly traded and privately held companies in the healthcare, life sciences, technology, and engineering industries.
Nancy Dreyer, Ph.D., a 2020 Red Jacket honoree, is Chief Scientific Officer for IQVIA Real World Solutions. IQVIA is a leading global provider of advanced analytics, technology solutions, and contract research services to the life-sciences industry. She leads the scientific activities and heads the Center for Advanced Evidence Generation. She is an expert in conducting studies of comparative effectiveness, safety, value, and sports injuries using existing data or creating appropriate evidence with fit-for-purpose approaches including randomized pragmatic trials. She also actively contributes to the development of quality standards for real-world evidence, collaborating with various national agencies and professional societies. Nancy is also an Adjunct Professor of Epidemiology at the University of North Carolina at Chapel Hill.
Follow on Twitter: @IQVIA_global
Chief Scientific Officer and Senior VP, Real World Solutions, IQVIA
Eric Dube, Ph.D., a 2020 PharmaVOICE 100, is the President and CEO of Retrophin; he also serves as a member of the company's board of directors. He oversees a global team dedicated to identifying, developing, and delivering life-changing therapies to people living with rare disease. He is a results-driven leader who is committed to patients and integrating their perspective into all aspects of the company’s operations. Before joining Retrophin, Dr. Dube was President and Head of North America at ViiV Healthcare. With leadership experience across the United States, Europe, and Japan, Dr. Dube draws upon significant expertise in managing commercial, operations, market access, medical and business development functions.
Dr. Cameron Durrant, a Red Jacket Award honoree, serves as Chairman and CEO of Humanigen, a clinical-stage biopharmaceutical company developing next-generation cell and gene therapies for the treatment of cancers, whose fortunes he turned around when he took the helm in 2016. Cameron has served as CEO of three other specialty pharmaceutical companies, helping to turn around every company he has led. In addition, he has held senior roles at Pharmacia (now part of Pfizer) and Johnson & Johnson. He has launched five blockbusters during his career.
Joe Dustin is the recently appointed Head of Clinical Innovation at Bristol Myers Squibb, a global biopharmaceutical company whose mission is to discover, develop and deliver innovative medicines that help patients prevail over serious diseases. Joe is a noted innovator sitting at the intersection of life sciences and technology with goals focused on making the whole drug development process faster for pharma and better for patients. For almost 20 years, Joe has been a vocal and visible force in the life-sciences industry specifically in the realm of eClinical technology starting in the eCOA space, and most recently finishing up a 12-year run with Medidata. He has worked with top pharmaceutical, biotech, and CRO organizations on innovation, change management, implementation, product development, sales and consulting. He is a member of the Drug Information Association’s Regional Advisory Council and the Leadership Council for the CNS Summit.
Dr. Elizabeth Garner, a 2019 PharmaVOICE 100, serves as Chief Medical Officer for ObsEva, a clinical-stage biopharmaceutical company ushering in a new era in women’s reproductive health. A seasoned senior executive with over a decade of experience in a range of therapeutics areas in the pharmaceutical and diagnostics industries, she has extensive clinical trials experience, with expertise in women's health and cancer prevention, including vaccines and diagnostics. Elizabeth trained in obstetrics and gynecology and gynecologic oncology at Brigham and Women's Hospital, Massachusetts General Hospital, and the Dana Farber Cancer Institute. She earned her M.D. from Harvard Medical School and an MPH in International Health from Harvard T.H. Chan School of Public Health.
Adlai Goldberg, a 2020 PharmaVOICE 100, is EY’s Global Life Sciences Digital, Social and Commercial Innovation Leader, with a focus on developing the necessary digital infrastructure to support emerging, next-generation forms of individualized therapies to tackle cancer and rare diseases. EY’s purpose is to build a better working world. With more than 28 years of professional experience in media, communications, and consulting to his credit, Adlai helped establish the EY global social media services and analytics hub as well as Pointellis, a digital ecosphere that expedites the timely flow of information and materials along the value chain, helping patients receive the care they need. Additionally, he has also helped launch the world’s first interactive television platform in Hong Kong.
Follow on Twitter at: @adlaigoldberg @EY_health
Global Digital, Social and Commercial Innovation Life Sciences Leader, EY
Guy Goldberg has served as Chief Business Officer of RedHill Biopharma, a specialty biopharmaceutical company primarily focused on gastrointestinal diseases, for the last eight years. Before joining RedHill, Guy served as Senior VP of Business Operations at Eagle Pharmaceuticals, a specialty injectable drug development company. Previously, he was a member of the investment team at ProQuest Investments, a healthcare-focused venture capital firm. He previously served as a consultant at McKinsey & Company.
Barry Greene, a 2020 Red Jacket honoree, joined Alnylam, which is harnessing the potential of RNAi therapeutics to transform the lives of people living with diseases for which there are limited or inadequate treatment options, in 2003. He has more than 25 years of experience in healthcare, pharmaceutical, and biotechnology industries. Before Alnylam, Barry was General Manager of Oncology at Millennium Pharmaceuticals, where he led the company’s global strategy and execution for its oncology business, including strategic business direction and execution, culminating in the successful approval and launch of Velcade in mid-2003. Barry also serves on the Boards of Acorda Therapeutics and Karyopharm Therapeutics.
Mary Frances Harmon, a 2020 PharmaVOICE 100, brings more than 30 years of experience in the pharmaceutical industry to her role as Senior VP of Corporate and Patient Relations at PTC, which focuses on the development of orally administered small molecule drugs that regulate gene expression by targeting post-translational control mechanisms in orphan diseases. She oversees strategic and operational leadership for policy, advocacy, and patient communications and engagement. Her work helps create a unified vision for patient and government relations and implementing programs with patient groups. Before PTC, Mary Frances was the Head of Global Patient Advocacy at NPS Pharmaceuticals. In 2020, she received the Annual Heart of BioNJ award for her commitment to creating a unified vision for patients and implementing programs with patient groups.
Follow on Twitter: @PTCBio
Senior VP, Corporate and Patient Relations, PTC Therapeutics
Guadalupe Hayes-Mota, a 2020 PharmaVOICE 100, is Director, Global Supply Chain and Manufacturing at Ultragenyx Pharmaceuticals, a clinical-stage biopharmaceutical company committed to bringing to market novel products for the treatment of rare and ultra-rare diseases. He leads the worldwide packaging, labeling, and distribution of the company's gene therapy medicines and supplies. Previously, he led the global production and distribution of medicines to 93 countries at Biogen and GSK. He also ran 12 free healthcare clinics for underserved-populations (UCLA Health) and helped to develop and implement the Affordable Care Act at RAND Corporation. His healthcare leadership also extends to public life as an advocate for patient healthcare access.
Follow on Twitter: @MotaHayes
Director, Global Supply Chain and Manufacturing, Ultragenyx Pharmaceuticals
Erin Horvath, a 2020 PharmaVOICE 100, is the President of Distribution Services at AmerisourceBergen, which is dedicated to advancing connections across healthcare. Erin is focused on ensuring the company’s customers and their patients get the therapies they need, when they need them. Since taking the helm, she has overseen significant organizational efficiencies, improved metrics, and enhanced customer experiences. She joined AmericsourceBergen from SMART Business Advisory and Consulting.
Follow on Twitter: @Healthcare_ABC
President, Distribution Services, AmerisourceBergen Corp.
Barby Ingle, a 2020 PharmaVOICE 100, is President of the International Pain Foundation, which educates and supports chronic pain patients, specifically those with neuropathy pain conditions, around the world. A chronic pain educator, patient advocate, as well as a motivational speaker and author on pain topics, she has been a pain patient since developing endometriosis in 1997, and reflex sympathetic dystrophy in 2002. Late last year, Barby wrapped up Season 8 of the live digital-TV webisode of The Ken and Barby Show with her husband Ken Taylor. She also volunteers for Reality Rally, Global Genes, RDLA, CPATF, and other charities.
Rob Jekielek is Managing Director of Harris Poll, which has been tracking U.S. public opinion, motivations, and social sentiment since 1963. Rob has more than 18 years of experience building and leading corporate brand and reputation development relationships. He has extensive expertise building and implementing solutions for companies with varied business models and has worked across North America, Europe, and South Africa in a variety of industries and sectors. Rob regularly works across functions and for both corporate and business line leaders. Rob has lectured at a number of leading universities.
Dr. Amir Kalali is a Red Jacket honoree and Chief Curator and Chairman of the CNS Summit, which was founded in 2009 by R&D leaders in life sciences, to advance clinical development, with a focus on innovation, collaboration, and technology. Dr. Kalali is a an innovator at the intersection of life sciences and technology, advising companies on building the future of their business at the board level or as a strategic advisor. He sits on the board of directors of both private and publicly traded companies. Dr. Kalali has been involved in hundreds of clinical development programs, and multiple successful NDAs for new treatments for patients. He is Professor of Psychiatry at University of California San Diego, Editor of the journal Innovations in Clinical Neuroscience, and the Lead Editor of the book Essential CNS Drug Development, published by Cambridge University Press. He has authored over 150 peer-reviewed publications. Dr. Kalali was the Founding Chairman of the Executive Committee of the International Society for CNS Drug Development (ISCDD), a founding member of the International Society for CNS Clinical Trials and Methodology (ISCTM), where he serves on the Executive Committee, the Scientific Committee, and previously chaired the Membership and Publication Committees.
Jay is an advisor for Health2047, which is partnering with the AMA to transform healthcare at the system level. In addition, Jay also is an adviser for Saama. He is adept at shaping strategy, driving execution while nurturing culture and is passionate at bringing innovative therapeutics to enhance the lives of patients. Previously, he served as Chief Operating Officer for Celularity, a clinical stage cell therapeutics company and before that he spent 21 years with Celgene in increasingly senior roles, most recently as Senior VP, Global Clinical Research and Development Operations.
Suresh Katta, a 2018 PharmaVOICE 100, is the Founder and CEO of Saama Technologies. Under his stewardship, Saama, which was founded in 1997, harnesses and applies the power of artificial intelligence and deep learning to its proprietary analytics platform. Suresh had a vision to help organizations discover value and insights from disparate data streams in their ecosystem, and well before the term “big data” became ubiquitous. Suresh has also successfully launched two other startups. He previously worked at Silicon Graphics, holding many different engineering roles.
Follow on Twitter: @sureshkattasaam @saamatechinc
Michelle Keefe, a Red Jacket honoree, is President, Commercial Operations at Syneos Health, a fully integrated biopharmaceutical solutions organization. An accomplished healthcare executive, Michelle has a proven ability to identify and capitalize on opportunities in the marketplace to improve competitive performance and deliver exceptional results. She has more than 25 years of life-sciences industry experience. Before Syneos, she served as Global Group President and Chief Development Officer at Publicis Health. In addition, she has served as VP, Business Development for The Visiting Nurse Service of New York.
Follow on Twitter: @SyneosHealth
Michele Keefe, President, Commercial Solutions, Syneos Health
Tami Klerr, a 2012 PharmaVOICE 100, is Executive VP and Chief Business Development and Marketing Officer at PRA Health Sciences, a global healthcare intelligence partner, that helps develop life-saving and life-improving drugs with a comprehensive suite of clinical development services, including data management, statistical analysis, clinical trial management, medical writing, and regulatory and drug development consulting. Tami is responsible for global business development, marketing, and strategic planning for the contract research organization. She joined PRA from InfaCare Pharmaceutical Corp., where she held the position of VP of Clinical Operations. Before that, Tami spent 13 years with Pharmaceutical Product Development in a variety of senior roles in business development, key account management and operations.
Follow on Twitter: @PRAHSciences
Executive VP and Chief Business Development and Marketing Officer, PRA Health Sciences
Craig Lipset, a Red Jacket honoree, is Founder of Clinical Innovation Partners, which provides growth advisory services for organizations developing and implementing innovative approaches for clinical research and medicine development. Craig is an advisor to technology and biopharmaceutical companies, universities, and the venture community, bringing vision to the intersection of research, digital solutions, and patient engagement. Craig was the Head of Clinical Innovation and Venture Partner at Pfizer, on the founding Operations Committee for TransCelerate Biopharma, and on the founding management teams for Perceptive Informatics and Adnexus Therapeutics. He serves on the Board of Directors for the Foundation for Sarcoidosis Research and the MedStar Health Research Institute, and on the Editorial Board for Therapeutic Innovation & Regulatory Science. Craig is an Adjunct Assistant Professor in Health Informatics at Rutgers University, and an Adjunct Instructor at the University of Rochester Center for Health + Technology.
Wendy Lund, a 2020 PharmaVOICE 100, is CEO of GCI Health, a global, integrated healthcare communications agency. Through her almost 30 years of healthcare communications and marketing experience, Wendy has worked with a diverse group of pharmaceutical, biotech, medical technology companies globally and in the U.S. on a corporate level and across a variety of disease categories. Before joining GCI Health, Wendy was with MS&L for 12 years and, as Executive VP, Global Business and Client Development, she was the only woman on the global leadership team.
Amir Malka is President and Co-Founder of Bioforum and, since its formation in 1998, has led the company to become a data-focused CRO, committed to helping companies understand the value of their clinical data. He brings his extensive background in the life-sciences industry, and in particular in clinical trials, to drive innovative clinical trial services. In addition, Amir is a member of several life-sciences and clinical trial associations and active advocate in helping break down barriers to help further advance medical industries in Israel.
Follow on Twitter: @amirmalka @BioforumM
President and Co-Founder, Bioforum the Data Masters
Steve Matas, a 2020 PharmaVOICE 100, serves as Senior VP, Strategic Resourcing at Advanced Clinical, a full-service CRO that delivers functional support, quality and validation, patient recruitment, and retention, and strategic talent acquisition solutions. He has more than 20 years of strategic staffing experience across the information technology and life-sciences industries. Before joining Advanced Clinical, Steve served as VP of Sales, Health and Life Sciences, IT Staffing and Solutions at DISYS, where he was responsible for the healthcare and life sciences technology practice and supported 15 of the largest global healthcare and life sciences clients.
Andrea McGonigle, a Red Jacket honoree, is Managing Director, Health & Life Science Business Development, at Microsoft, which is focused on empowering healthcare organizations of all sizes to reimagine the ways they bring together people, processes, and health data insights to improve care delivery. A thought leader in patient engagement and cloud compliance, Andrea helps her team focus on a holistic approach to health and driving initiatives among the diverse companies that intersect the health world. A multi-award-winner, before joining Microsoft Andrea worked for Merck, most recently as Manager, Enterprise Collaboration and Content Management.
Follow on Twitter: @andreawork @Microsoft
Managing Director, Health & Life Science Business Development, Microsoft
Clive Meanwell, M.D., Ph.D., a 2016 PharmaVOICE 100, founded The Medicines Company, a biopharmaceutical company in 1996. In 2019, Novartis acquired the company. Clive, who is a pharmaceutical and biotechnology executive committed to authentic innovation, had served as the company’s Chief Innovation Officer since December 2018 and as the company’s CEO. Before founding the company, he held various positions at Hoffmann-La Roche. He holds an MB ChB (M.D. equivalent) and a Ph.D. from the University of Birmingham, UK.
Susanne Munksted is Chief Precision Officer of Diaceutics, a data analytics and end-to-end services provider enabled by DXRX. She brings a wealth of experience to her role leading a global commercial team to improve the testing ecosystem to help patients capitalize on the new breakthrough medications. Susanne has a broad commercial work experience from both pharma and diagnostic companies and provides insights and builds strategies for unique personalized medicine projects. In past roles Susanne was leading teams focused on commercialization of CDx in alignment with Rx launch and life cycle across global territories and she has led a number of global launches of companion diagnostic products.
Mario Nacinovich, a 2011 and 2005 PharmaVOICE 100, is the VP of Marketing of Eyevance Pharmaceuticals. He is responsible for developing and implementing marketing strategies for Eyevance’s innovative and impactful ophthalmic therapies for the ocular surface and anterior segment and leading the marketing team. Mario joined the U.S. Human Health division of Merck & Co., Inc. in 1994. He went on to become VP of Ophthalmology (under agency contract with Pharmacia) and VP of Business Development and Strategic Planning at inVentiv Health (now Syneos). He co-founded and served as Co-CEO of Fission Communications (now Caudex Medical). He later served as VP of Business Development and Strategic Planning at QD Healthcare (now Guidemark Health). Mario went on to become managing partner of AXON, where he initiated and led the firm’s consultancy in healthcare for nearly a decade in the U.S., while serving on the Board of Directors and several committees for Avenir Global. Most recently, he led all communications, marketing, and commercial operations at AiCure and consulted on global medical affairs with Santen, Inc.
Dave Ormesher, a Red Jacket Award honoree, is founder and CEO of closerlook. Dave has taken the digital marketing agency from a small, creative media boutique and grown it into a recognized leader in creating technology-based relationship marketing solutions helping pharmaceutical brands build meaningful relationships with healthcare professionals. In addition, he founded Bigger Future, a nonprofit business and leadership training program based in Rwanda. He serves on the Board of Directors of the Lurie Children’s Hospital Foundation, on the Innovation Board of XPRIZE Foundation, and on the board of the Lyric Opera of Chicago.
Kinnari Patel, Pharm.D., a 2018 PharmaVOICE 100, serves as Chief Operating Officer and Executive VP, Development, for Rocket Pharmaceuticals, which is developing best-in-class curative gene and cell therapies for patients with devastating diseases. She has spent 15 years in rare disease R&D, across regulatory science, pharmacovigilance, policy, and quality compliance at several large pharmaceutical companies. She has led both small molecule and biologic development programs from Phase I through Phase IV across multiple therapeutic areas including immuno-oncology, oncology, respiratory, virology, transplantation, and metabolism.
Follow on Twitter: @RocketPharma
Chief Operating Officer & Head of Development, Executive VP, Rocket Pharmaceuticals
Ahnal Purohit, Ph.D., a Red Jacket Award honoree, is Founder and CEO of Purohit Navigation, a healthcare firm providing strategic guidance and creative solutions to help healthcare brands, franchises, and companies. A multi-award-winning business leader, Ahnal entered the field of healthcare communications with the objective of delivering life-sciences companies research-based insights, deep strategic and scientific thinking, and breakthrough creative that would truly change behavior. In addition, Ahnal co-founded the nonprofit organization African Women’s Alliance in Support of Health (AWASH) to help the estimated 30,000 women among Sierra Leone’s total population of 6.5 million who suffer or die from vesicovaginal fistula. Ahnal is also a professor of statistics and behavioral science.
Anshal Purohit is President of Purohit Navigation, a healthcare firm providing strategic guidance and creative solutions to help healthcare brands, franchises, and companies. She is focused on ensuring the company executes on its vision of being the best partner for specialty brands in healthcare communications. She and her team provide strategy, market research, print, digital, promotional education, and public relations to clients. In addition, Anshal is a board member of the African Women’s Alliance in Support of Health (AWASH), which helps women in Sierra Leone who suffer from vesicovaginal and rectovaginal fistulas.
Nandini Ramani, a 2020 PharmaVOICE 100, is the Chief Operating Officer at Outcome Health, where she leads the revenue, product and operations functions to ensure the most rigorous health information platform, which includes more than 152,000 digital devices in over 40,000 physician offices and health systems across the country. She is a seasoned technologist, with a career spanning hardware and software across enterprise and consumer organizations, including her former role as VP of Twitter, running large global and diverse organizations.
Laura Randa, a 2018 and 2013 PharmaVOICE 100, serves as VP Market Access, Health Economics and Outcomes Research and Public Policy, for Mycovia Pharmaceuticals, which is developing breakthrough therapies in areas of unmet medical need, with an initial focus in women’s health. She has more than 22 years experience in market access, policy, specialty pharmacy, and trade and has launched 31 products in diverse disease categories. Previously, Laura was VP, National Accounts at Novartis, and before that she worked as Head of Payer Engagement at Regeneron, where she transformed how the company launches and markets products.
Follow on Twitter: @MycoviaPharma
VP Market Access, HEOR and Public Policy, Mycovia Pharmaceuticals
Mike Rea, a Red Jacket Award honoree, is Co-Founder and CEO of IDEA Pharma, a path-to-market design strategy practice that has supported more than 25% of the 50 fastest growing drugs in the past five years. A self-described pharma innovation protagonist/antagonist/geek, Mike previously was a Senior Fellow at FasterCures, a Center of the Milken Institute. He is also the creator of the annual Pharmaceutical Innovation Index and a multi-award winner in recognition of his influence in the biopharmaceutical industry. In his spare time, Mike is also Chief Musical Officer for Medical Records Limited, an indie record label.
Kanchan Relwani, M.D., a 2020 PharmaVOICE 100, is VP and Head of Medical Affairs at Alkermes. She has a deep-seated commitment to improving patients’ lives and has helped grow the medical affairs organization and expanded the scope and impact of the function within the company. She has spent more than 12 years in the pharmaceutical industry, starting at a medical affairs agency before moving to biotech and quickly transitioning to leadership positions. Kanchan has a medical degree from India, a post-doctoral research fellowship in ocular immunology from University College of London, and a post-doctoral research fellowship in the genetics of glaucoma from Harvard Medical School.
Julie Ross, a 2020 Red Jacket Award honoree, serves as President of Advanced Clinical, a full-service CRO that delivers functional support, quality and validation, patient recruitment, and retention, and strategic talent acquisition solutions. A recognized thought leader with more than 25 years of industry experience, Julie is at the forefront of championing initiatives to improve clinical research. Previously with inVentiv Health Clinical, Julie served as Senior VP of Global Strategic Services. She has a therapeutic specialty in urology and gastroenterology and previously served as Program Director for the School of Nuclear Medicine and Diagnostic Ultrasound at St. Mary's Hospital in Milwaukee. Julie also serves on the Board of Directors of the Healthcare Businesswomen’s Association.
Roslyn Schneider, M.D., a 2018 PharmaVOICE, is Principal of RozMD Patient Affairs Consulting, which is focused on patient-centric transformation of the biopharmaceutical industry. Previously, she was the Global Patient Affairs Lead driving patient-centricity within Pfizer's Medical Organization. Before Pfizer, she provided direct patient care at Beth Israel Medical Center NY, directed specialty programs for doctors in training, and was a Clinical Professor of Medicine at the Albert Einstein College of Medicine. She is a fellow of the American College of Physicians and the American College of Chest Physicians. She is also a former board member of the Healthcare Businesswomen’s Association. She received her M.D. from Mount Sinai School of Medicine and her MSc in Pharmaceutical Medicine from Hibernia College.
Jessica Scott, M.D., JD, a 2020 PharmaVOICE 100, is Head of R&D Patient Engagement at Takeda Pharmaceutical, a global, research and development-driven pharmaceutical company. Jessica is helping the company focus on its goal of developing medicines with patients rather than for patients. Her background as a lawyer and physician brings a unique combination of medical and legal process to Takeda. She employs disruptive and innovative thinking in rapidly changing environments to improve the lives of patients. Before joining Takeda, she led efforts related to clinical trial transparency, patient centricity initiatives, bioethical issues, and the development of GSK’s approach to sharing aggregate results of clinical trial in plain language. Dr. Scott received her M.D. from Tufts University School of Medicine in Boston. Dr. Scott has served on the NC Bar Association Health Law Section Council and the Ethics Committee.
Follow on Twitter: @JSScottMDJD
Head of R&D Patient Engagement Office, Takeda Pharmaceutical Company
Leerom Segal, a Red Jacket honoree, is Founding Partner and Chairman at Klick, an independent commercialization partner for life sciences that is laser-focused on launching and enabling life-sciences brands to maximize their full market potential. An accomplished strategist and technologist, Leerom is committed to surpassing client expectations and building long-term relationships. He has achieved numerous accolades, including EY’s Young Entrepreneur of the Year award, "Entrepreneur of the Year" by the Business Development Bank of Canada, and a "Top 40 Under 40" by The Globe & Mail. He serves on both public and private boards. Leerom launched his first business at age 12 and was named Chief Technology Officer of the publicly traded Motion Works Group by the time he was 16.
Craig Serra, a 2020 PharmaVOICE 100, is Global Head, Innovation, Data Operations, at Novartis, a global healthcare company that provides solutions to address the evolving needs of patients worldwide. He is focused on driving innovation for data operations, comprised of almost 1000 associates. Previously he was Senior Director, Clinical Delivery Transformation, Clinical Operations, R&D Solutions for IQVIA, helping to lead a global enterprisewide eTMF transformation initiative across all clinical operations. Before that, he was Senior Director, Clinical Sciences and Operations, at Pfizer. Craig is on the board of directors for the Cristian Rivera Foundation, which is seeking to cure diffuse intrinsic pontine glioma.
Robin Shapiro, a 2020 PharmaVOICE 100, is CEO of TBWA\WorldHealth, a global healthcare advertising and communications company, where she is bringing disruptive thinking to some of the world’s most ambitious healthcare brands. Robin has contributed to many successful history-shaping healthcare launches and has created an agency environment in which innovation, creativity, and positivity thrive. She joined TBWA\WorldHealth in 2016, as Group President, North America for TBWA\Worldhealth, was named Global President of the company in 2017, and was promoted to CEO in March 2020. Before TBWA, she served as President and Chief Creative Officer at Corbett.
Follow on Twitter: @RobinShapiro2, @tbwaworldhealth, @OmnicomHealth
Jeffrey W. Sherman, M.D., a 2020 PharmaVOICE 100, is Executive VP and Chief Medical Officer, at Horizon, where he is not only changing the lives of people with rare disorders by working on innovative treatments, but his involvement with dozens of industry associations is elevating the patient voice in drug development, approval, and use. Before joining Horizon, Dr. Sherman served as Chief Medical Officer at IDM Pharma, which was acquired by Takeda. He has also served in senior roles at Takeda Global Research and Development, NeoPharm, and Searle/Pharmacia. He currently serves as a DIA liaison to the FDA Clinical Trial Transformation Initiative (CTTI) and is on the board of advisors of the Center for Information and Study on Clinical Research Participation (CISCRP). He is also an adjunct assistant professor of medicine at the Northwestern University Feinberg School of Medicine and serves on the board of directors of Strongbridge Biopharma and Xeris Pharmaceuticals. He received his medical degree from the Rosalind Franklin University/Chicago Medical School.
Follow on Twitter: @HorizonNews
Executive VP and Chief Medical Officer, Horizon Therapeutics
Deb Tatton, a 2020 PharmaVOICE 100, serves as Senior VP, Global Clinical Operations, Parexel, where she oversees a 5,000-plus team across study start up, monitoring, site management, and clinical operation leaders across the company’s clinical studies. She is responsible for leading the solution development teams and proactively engaging with experts across Parexel to create bespoke solutions that maximize value for clients. Deb leverages her strong operational expertise to establish cohesive relationships across multiple stakeholders within the company and sponsor organizations to ensure seamless execution from pre-sales through project closure. She joined Parexel, which through a suite of services helps life-sciences and biopharmaceutical customers across the globe transform scientific discoveries into new treatments for patients, in 1997 and has advanced to increasingly more senior roles over her career.
Kent Thoelke, a 2013 PharmaVOICE 100, is Executive VP and Chief Scientific Officer at PRA Health Sciences, a global healthcare intelligence partner that helps develop life-saving and life-improving drugs with a comprehensive suite of clinical development services, including data management, statistical analysis, clinical trial management, medical writing, and regulatory and drug development consulting. He is a pioneer in the application of mobile first strategies, which integrate clinical trials and provide access directly to patients in both virtual and hybrid-virtual models. With more than 25 years of experience in the global drug development, diagnostic, and device industry, Kent understands the global drug development environment and maintains established relationships with international therapeutic experts in several indications. He has lectured on his experience in the current landscape of clinical trial recruitment and drug development timelines.
Follow on Twitter: @KentThoelke @PRAHSciences
Executive VP and Chief Scientific Officer, PRA Health Sciences
Rebecca Vermeulen, a 2020 PharmaVOICE 100, is VP Patient and Society Strategy, Product Development and Head Customer Strategy, Patient Partnership and Health Equity Global Medical Affairs, at Roche, a global pioneer in pharmaceuticals and diagnostics focused on advancing science to improve people’s lives. She champions efforts to give patients the information they need and bring insight into the research and development of new treatments as a valued trusted partner in the process. Before joining Roche as Head of Global Medical Liaisons and Communications, she spent nearly eight years at Genentech in increasingly senior roles. Rebecca also serves as Chair, Global Board of Directors, for the Healthcare Businesswomen’s Association. She has also served as Chair, Global Board of Directors, for the Drug Information Association.
Wendy White, a Red Jacket honoree, is Co-founder of RareiTi, which offers a new system of care for people and communities across the globe with unmet needs in the rare disease space. She is an innovative leader working for more than 20 years in rare disease at the intersection of advocacy, technology, and business. She is a serial entrepreneur having worked to integrate patient-level insights into all aspects of the drug delivery continuum. She is the mother of a child with a rare disorder and publisher and co-author of Uncommon Challenges; Shared Journeys—Stories of Love, Hope, and Community by Rare Disease Caregivers. Her background includes four consecutive years on the Inc 5000 fastest growing company list. She currently serves as Chair of Global Genes and Chair Emeritus for the Healthcare Businesswomen’s Association (HBA).